- Email: [email protected]
Correction to Lancet Oncol 2015; 16: 1045
Corrections
Correction to Lancet Oncol Correction to Lancet Oncol 2015; 16: 1045 2015; 16: 1499 Tournigand C, Chibaudel B, Samson B, et al. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal
Hegewisch-Becker S, Graeven U, Lerchenmüller CA, et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, noninferiority, open-label phase 3 trial. Lancet Oncol 2015; 16: 1355–69—The fourth line of the Findings section of the Summary of this Article should read “Bevacizumab alone was noninferior to standard fluoropyrimidine plus bevacizumab (hazard ratio [HR] 1·08 [95% CI 0·85–1·37]; p=0·53; upper limit of the one-sided 98·8% CI 1·42), whereas no treatment was not (HR 1·26 [0·99–1·60]; p=0·056; upper limit of the one-sided 98·8% CI 1·65).” In figure 5, in the Overall row, the n/N entry for the fluoropyrimidine plus bevacizumab group should read 131/147. These corrections have been made to the online version as of Nov 29, 2015.
www.thelancet.com/oncology Vol 16 December 2015
Progression-free survival from maintenance (%)
Correction to Lancet Oncol 2015; 16: 1355, 1363
A 100
n Bevacizumab 228 Bevacizumab plus erlotinib 224
75
Events (n)
Median (95% CI)
187 169
4·9 (4·1-5·7) 5·4 (4·3-6·2)
Stratified hazard ratio 0·81 (0·66–1·01) p=0·059 (log-rank) Unstratified hazard ratio 0·78 (0·68–0·96) p=0·019 (log-rank) Restricted mean survival (maximum follow-up 24 weeks) p=0·023
50
25
0 0 Number at risk Bevacizumab 228 Bevacizumab 224 plus erlotinib
6
12
18
24
30
79 83
16 30
8 12
2 5
0 2
Events (n)
Median (95% CI)
177 154
22·1 (19·6–26·7) 24·9 (21·4–28·9)
B
n
100 Overall survival from maintenance (%)
Bear HD, Tang G, Rastogi P, et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol 2015; 16: 1037–48—In table 3 of this Article, the percentage of local recurrences in the “with bevacizumab group” should read 1%. This correction has been made to the online version as of Nov 29, 2015.
cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. Lancet Oncol 2015; 16: 1493–1505—In this Article, the colours of the curves in both panels of figure 3 were inverted; the correct version is shown below. These corrections have been made to the online version as of Nov 29, 2015.
Bevacizumab 228 Bevacizumab plus erlotinib 224
Stratified hazard ratio 0·79 (0·63–0·99) p=0·036 (log-rank) Unstratified hazard ratio 0·79 (0·64–0·98) p=0·035 (log-rank) Restricted mean survival (maximum follow-up 24 weeks) p=0·024
75
50
25
0 0 Number at risk Bevacizumab 228 Bevacizumab 224 plus erlotinib
12
24
36
48
60
41 49
12 22
3 8
Time (months) 168 172
95 95
e589
Correction to Lancet Oncol Correction to Lancet Oncol 2015; 16: 1045 2015; 16: 1499 Tournigand C, Chibaudel B, Samson B, et al. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal
Hegewisch-Becker S, Graeven U, Lerchenmüller CA, et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, noninferiority, open-label phase 3 trial. Lancet Oncol 2015; 16: 1355–69—The fourth line of the Findings section of the Summary of this Article should read “Bevacizumab alone was noninferior to standard fluoropyrimidine plus bevacizumab (hazard ratio [HR] 1·08 [95% CI 0·85–1·37]; p=0·53; upper limit of the one-sided 98·8% CI 1·42), whereas no treatment was not (HR 1·26 [0·99–1·60]; p=0·056; upper limit of the one-sided 98·8% CI 1·65).” In figure 5, in the Overall row, the n/N entry for the fluoropyrimidine plus bevacizumab group should read 131/147. These corrections have been made to the online version as of Nov 29, 2015.
www.thelancet.com/oncology Vol 16 December 2015
Progression-free survival from maintenance (%)
Correction to Lancet Oncol 2015; 16: 1355, 1363
A 100
n Bevacizumab 228 Bevacizumab plus erlotinib 224
75
Events (n)
Median (95% CI)
187 169
4·9 (4·1-5·7) 5·4 (4·3-6·2)
Stratified hazard ratio 0·81 (0·66–1·01) p=0·059 (log-rank) Unstratified hazard ratio 0·78 (0·68–0·96) p=0·019 (log-rank) Restricted mean survival (maximum follow-up 24 weeks) p=0·023
50
25
0 0 Number at risk Bevacizumab 228 Bevacizumab 224 plus erlotinib
6
12
18
24
30
79 83
16 30
8 12
2 5
0 2
Events (n)
Median (95% CI)
177 154
22·1 (19·6–26·7) 24·9 (21·4–28·9)
B
n
100 Overall survival from maintenance (%)
Bear HD, Tang G, Rastogi P, et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol 2015; 16: 1037–48—In table 3 of this Article, the percentage of local recurrences in the “with bevacizumab group” should read 1%. This correction has been made to the online version as of Nov 29, 2015.
cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. Lancet Oncol 2015; 16: 1493–1505—In this Article, the colours of the curves in both panels of figure 3 were inverted; the correct version is shown below. These corrections have been made to the online version as of Nov 29, 2015.
Bevacizumab 228 Bevacizumab plus erlotinib 224
Stratified hazard ratio 0·79 (0·63–0·99) p=0·036 (log-rank) Unstratified hazard ratio 0·79 (0·64–0·98) p=0·035 (log-rank) Restricted mean survival (maximum follow-up 24 weeks) p=0·024
75
50
25
0 0 Number at risk Bevacizumab 228 Bevacizumab 224 plus erlotinib
12
24
36
48
60
41 49
12 22
3 8
Time (months) 168 172
95 95
e589